Gloria  Galvan

Ms. Gloria Galvan

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 December 2017 in Vaccines
Verified
Journal Article
Open access
PDF file
AKArshad Khan
Arshad Khan
SSShailbala Singh
Shailbala Singh
GGloria Galvan
Gloria Galvan
CJChinnaswamy Jagannath
Chinnaswamy Jagannath
JSJagannadha Sastry
Jagannadha Sastry
Infection by Mycobacterium tuberculosis (Mtb) remains a major global concern and the available Bacillus Calmette-Guerin (BCG) vaccine is poorly efficacious in adults. Therefore, alternative vaccines and delivery strategies focusing on Mtb antigens and appropriate immune stimulating adjuvants are needed to induce protective immunity targeted to the lungs, the primary sites of infections and pathology. We present here evidence in support of mucosal vaccination by the sublingual route in mice using the subunit Mtb antigens Ag85B and ESAT-6 adjuvanted with the glycolipid alpha-galactosylceramide (α-GalCer), a potent natural killer T (NKT) cell agonist. Vaccinated animals exhibited strong antigen-specific CD4 and CD8 T cells responses in the spleen, cervical lymph nodes and lungs. In general, inclusion of the α-GalCer adjuvant significantly enhanced these responses that persisted over 50 days. Furthermore, aerosolized Mtb infection of vaccinated mice resulted in a significant reduction of bacterial load of the lungs and spleens as compared to levels seen in naïve controls or those vaccinated with subunit proteins, adjuvant , or BCG alone. The protection induced by the Mtb antigens and-GalCer vaccine through sublingual route correlated with a TH1-type immunity mediated by antigen-specific IFN-γ and IL-2 producing T cells.

14 September 2018 in Cancer Research
Verified
Journal Article
Closed access
PDF file
SDStephanie Dorta-Estremera
Stephanie Dorta-Estremera
RCRenee L. Chin
Renee L. Chin
GGloria Galvan
Gloria Galvan
CNCourtney Nicholas
Courtney Nicholas
AYAnanta V. Yanamandra
Ananta V. Yanamandra
JSJagannadha Sastry
Jagannadha Sastry
High-risk human papillomavirus (HPV)–associated squamous cell carcinomas of the oropharynx (SCCOP) are among the fastest growing cancers. After standard-of-care treatment, however, patients with HPV+ SCCOP have better overall and disease-specific survival than patients with HPV− SCCOP, suggesting the importance of HPV-specific immunity. We reasoned that therapeutic vaccination targeting the HPV-16 E6 and E7 oncogenes could elicit high-affinity, high-frequency tumor antigen–specific T-cell responses, which could then be augmented and shielded from suppression in the tumor microenvironment by immune checkpoint modulation. In this study, we used a preclinical syngeneic mouse model of oral cancer comprised of mouse tonsil-derived epithelial cells stably expressing HPV-16 E6 and E7 genes along with H-ras oncogene (mEER) to identify combinations of vaccination and checkpoint antibodies capable of promoting tumor regression. Intranasal HPV E6/E7 peptide vaccination and single checkpoint antibodies failed to elicit responses in more than half of animals; however, 4-1BB agonist antibody along with either CD40 agonist antibody or CTLA-4 blockade eliminated the majority of established mEER tumors. The combination of intranasal HPV peptide vaccine and α4-1BB and αCTLA-4 antibodies produced curative efficacy and a better safety profile against orally implanted mEER tumors. Correlates of protective immunity included enhanced intratumoral levels of CD8 T cells relative to immunosuppressive regulatory T cells and myeloid-derived suppressor cells. Overall, our results demonstrate combination vaccine-immunotherapy modalities as novel treatment options for HPV+ SCCOP. Significance: Combinations of vaccine and checkpoint modulation are effective and safe treatment options for HPV+ oral cancers. Cancer Res; 78(18); 5327–39. ©2018 AACR.

29 May 2020 in Vaccines
Verified
Journal Article
Open access
PDF file
GGloria Galvan
Gloria Galvan
Stephanie Dorta-EstremeraStephanie Dorta-Estremera
Stephanie Dorta-Estremera
Venkatesh L HegdeVenkatesh L Hegde
Venkatesh L Hegde
SNSita M. K. Nookala
Sita M. K. Nookala
AYAnanta V. Yanamandra
Ananta V. Yanamandra
JSJagannadha Sastry
Jagannadha Sastry
Human papillomavirus (HPV)-induced cancers continue to affect millions of women around the world, and the five year survival rate under the current standard of care for these cancers is less than 60% in some demographics. Therefore there is still an unmet need to develop an effective therapy that can be easily administered to treat established HPV cervical cancer lesions. We sought to investigate the potential of an intranasal HPV peptide therapeutic vaccine incorporating the combination of α-Galactosylceramide (α-GalCer) and CpG-ODN adjuvants (TVAC) against established HPV genital tumors in a syngeneic C57BL/6J mouse model. We obtained evidence to show that TVAC, delivered by the mucosal intranasal route, induced high frequencies of antigen-specific CD8 T cells concurrent with significant reduction in the immunosuppressive regulatory T cells and myeloid derived suppressor cells in the tumor microenvironment (TME), correlating with sustained elimination of established HPV genital tumors in over 85% of mice. Inclusion of both the adjuvants in the vaccine was necessary for significant increase of antigen-specific CD8 T cells to the tumor and antitumor efficacy because vaccination incorporating either adjuvant alone was inefficient. These results strongly support the utility of the TVAC administered by needle-free intranasal route as a safe and effective strategy for the treatment of established genital HPV tumors.

31 March 2023
Verified
Other
Open access
SDStephanie Dorta-Estremera
Stephanie Dorta-Estremera
RCRenee L. Chin
Renee L. Chin
GGloria Galvan
Gloria Galvan
CNCourtney Nicholas
Courtney Nicholas
AYAnanta V. Yanamandra
Ananta V. Yanamandra
KSK. Jagannadha Sastry
K. Jagannadha Sastry
Gating strategy to analyze TILs after immunotherapy combinations

31 March 2023
Verified
Other
Open access
SDStephanie Dorta-Estremera
Stephanie Dorta-Estremera
RCRenee L. Chin
Renee L. Chin
GGloria Galvan
Gloria Galvan
CNCourtney Nicholas
Courtney Nicholas
AYAnanta V. Yanamandra
Ananta V. Yanamandra
KSK. Jagannadha Sastry
K. Jagannadha Sastry
Sequential treatment of vaccine and immune checkpoint modulation

31 March 2023
Verified
Other
Open access
SDStephanie Dorta-Estremera
Stephanie Dorta-Estremera
RCRenee L. Chin
Renee L. Chin
GGloria Galvan
Gloria Galvan
CNCourtney Nicholas
Courtney Nicholas
AYAnanta V. Yanamandra
Ananta V. Yanamandra
KSK. Jagannadha Sastry
K. Jagannadha Sastry
Therapeutic efficacy of immunotherapy combinations correlates with the presence of TcEO cells in the tumors